137 related articles for article (PubMed ID: 36291780)
1. A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors.
Patnaik A; Hamilton E; Xing Y; Rasco DW; Smith L; Lee YL; Fang S; Wei J; Hui AM
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291780
[TBL] [Abstract][Full Text] [Related]
2. Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer.
Zhang J; Wang X; Wang X; Hui A; Wu Z; Tian L; Xu C; Yang Y; Zhang W; Hu X
Invest New Drugs; 2021 Dec; 39(6):1549-1558. PubMed ID: 34109484
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
[TBL] [Abstract][Full Text] [Related]
4. A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.
Mao L; Guo J; Zhu L; Jiang Y; Yan W; Zhang J; Hui AM; Yang Y; Diao L; Tan Y; Zhao H; Jiang Y; Wu Z; Si L
Eur J Cancer; 2022 Nov; 175():125-135. PubMed ID: 36113242
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
Cao J; Guo H; Ji D; Shen W; Zhang S; Hsieh CY; Xiong Cai S; Edward Tian Y; Xu C; Zhang P; Xu B
Oncologist; 2023 Dec; 28(12):e1259-e1267. PubMed ID: 37338150
[TBL] [Abstract][Full Text] [Related]
6. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
7. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Janku F; Kim TM; Iyer G; Spreafico A; Elez E; de Jonge M; Yamamoto N; van der Wekken AJ; Ascierto PA; Maur M; Marmé F; Kiladjian JJ; Basu S; Baffert F; Buigues A; Chen C; Cooke V; Giorgetti E; Kim J; McCarthy F; Moschetta M; Dummer R
Eur J Cancer; 2024 Jan; 196():113458. PubMed ID: 38039779
[TBL] [Abstract][Full Text] [Related]
8. A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.
Rodon J; Rodriguez E; Maitland ML; Tsai FY; Socinski MA; Berlin JD; Thomas JS; Al Baghdadi T; Wang IM; Guo C; Golmakani M; Clark LN; Gazdoiu M; Li M; Tolcher AW
ESMO Open; 2024 Apr; 9(4):102961. PubMed ID: 38640748
[TBL] [Abstract][Full Text] [Related]
9. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer.
Nokihara H; Nishio M; Yamamoto N; Fujiwara Y; Horinouchi H; Kanda S; Horiike A; Ohyanagi F; Yanagitani N; Nguyen L; Yaron Y; Borgman A; Tamura T
Clin Lung Cancer; 2019 May; 20(3):e317-e328. PubMed ID: 30718102
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors.
Seetharam M; Norman A; Allred J; Kong J; Opyrchal M; Ma WW; Lou Y; Dy GK; Mahipal A; Weroha J; Wahner-Hendrickson A; Reid JM; Adjei AA
Res Sq; 2024 Apr; ():. PubMed ID: 38746220
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Bardia A; Kaklamani V; Wilks S; Weise A; Richards D; Harb W; Osborne C; Wesolowski R; Karuturi M; Conkling P; Bagley RG; Wang Y; Conlan MG; Kabos P
J Clin Oncol; 2021 Apr; 39(12):1360-1370. PubMed ID: 33513026
[TBL] [Abstract][Full Text] [Related]
13. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
[TBL] [Abstract][Full Text] [Related]
15. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors.
Falchook G; Infante J; Arkenau HT; Patel MR; Dean E; Borazanci E; Brenner A; Cook N; Lopez J; Pant S; Frankel A; Schmid P; Moore K; McCulloch W; Grimmer K; O'Farrell M; Kemble G; Burris H
EClinicalMedicine; 2021 Apr; 34():100797. PubMed ID: 33870151
[TBL] [Abstract][Full Text] [Related]
16. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Bedard PL; Tabernero J; Janku F; Wainberg ZA; Paz-Ares L; Vansteenkiste J; Van Cutsem E; Pérez-García J; Stathis A; Britten CD; Le N; Carter K; Demanse D; Csonka D; Peters M; Zubel A; Nauwelaerts H; Sessa C
Clin Cancer Res; 2015 Feb; 21(4):730-8. PubMed ID: 25500057
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Bendell JC; Bischoff HG; Hwang J; Reinhardt HC; Zander T; Wang X; Hynes S; Pitou C; Campbell R; Iversen P; Farrington DL; Bell-McGuinn K; Thomas M
Invest New Drugs; 2020 Aug; 38(4):1145-1155. PubMed ID: 31707688
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors.
Doi T; Hewes B; Kakizume T; Tajima T; Ishikawa N; Yamada Y
Cancer Sci; 2018 Jan; 109(1):193-198. PubMed ID: 29059492
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
Geoerger B; Bourdeaut F; DuBois SG; Fischer M; Geller JI; Gottardo NG; Marabelle A; Pearson ADJ; Modak S; Cash T; Robinson GW; Motta M; Matano A; Bhansali SG; Dobson JR; Parasuraman S; Chi SN
Clin Cancer Res; 2017 May; 23(10):2433-2441. PubMed ID: 28432176
[No Abstract] [Full Text] [Related]
[Next] [New Search]
